Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-02-2007 | Original Paper

Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

Auteurs: Gahan J. Pandina, Cynthia A. Bossie, Eriene Youssef, Young Zhu, Fiona Dunbar

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 2/2007

Abstract

Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n = 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), P < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism.

vorige artikel Designing Research Studies on Psychosocial Interventions in Autism

volgende artikel Short Breaks Services for Children with Autistic Spectrum Disorders: Factors Associated with Service Use and Non-use

Aman, M. G. (2004). Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Seminars in Pediatric Neurology, 11, 225–228. PubMedCrossRef

Aman, M. G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K. D., et al. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9, 36–47. PubMed

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491. PubMed

Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41–57. PubMedCrossRef

American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders. Washington: American Psychiatric Press.

Arnold, L. E., Vitiello, B., McDougle, C., Scahill, L., Shah, B., Gonzalez, N. M., et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1443–1450. PubMedCrossRef

Carter, A. S., Volmar, F. R., Sparrow, S. S., Wang, J. J., Lord, C., Dawson, G., et al. (1998). The Vineland Adaptive Behavioral Scales: Supplementary norms of individuals with autism. Journal of Autism and Developmental Disorders, 28, 287–302. PubMedCrossRef

Chez, M. G., Memon, S., & Hung, P. C. (2004). Neurologic treatment strategies in autism: An overview of medical intervention strategies. Seminars in Pediatric Neurology, 11, 229–235. PubMedCrossRef

Chouinard, G., Ross-Chouinard, A., Annable, L., & Jones, B. D. (1980). Extrapyramidal symptom rating scale. The Canadian Journal of Neurological Sciences, 7, 233.

Dunbar, F., Kusumakar, V., Daneman, D., & Schultz, M. (2004). Growth and sexual maturation during long-term treatment with risperidone. American Journal of Psychiatry, 161, 918–920. PubMedCrossRef

Findling, R., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry, 64, 1362–1369. PubMedCrossRef

Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: An update. Journal of Autism and Developmental Disorders, 33, 365–382. PubMedCrossRef

Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D’Arrigo, C., Calamoneri, F., & Spina, E. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14, 39–47. PubMedCrossRef

Horner, R. H., Carr, E. G., Strain, P. S., Todd, A. W., & Reed, H. K. (2002). Problem behavior interventions for young children with autism: A research synthesis. Journal of Autism and Developmental Disorders, 32, 423–446. PubMedCrossRef

Malone, R. P., Maislin, G., Choudhury, M. S., Gifford, C., & Delaney, M. A. (2002). Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 140–147. PubMedCrossRef

Masi, G. (2004). Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs, 18, 1031–1052. PubMedCrossRef

Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2003). A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. The Journal of Clinical Psychiatry, 64, 1039–1047. PubMed

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al., Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321. PubMedCrossRef

McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. The American Journal of Psychiatry, 162, 1142–1148. PubMedCrossRef

Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 372–376. PubMedCrossRef

Posey, D. J., & McDougle, C. J. (2000). The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review of Psychiatry, 8, 45–63. PubMedCrossRef

Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled withdrawal study of risperidone in maintenance treatment of children and adolescents with disruptive behaviour disorder. American Journal of Psychiatry, 163, 402–410. PubMedCrossRef

Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980). Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10, 91–103. PubMedCrossRef

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. PubMedCrossRef

Sparrow, S., & Cicchetti, D. (1985). Diagnostic uses of the Vineland Adaptive Behavior Scales. Journal of Pediatric Psychology, 10, 215–225. PubMedCrossRef

Tassé, M. J., Aman, M. G., & Rojahn, J. (1996). The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities, 17, 59–75. PubMedCrossRef

Yeargin-Allsopp, M., Rice, C., Karapurkar, T., Doernberg, N., Boyle, C., & Murphy, C. (2003). Prevalence of autism in a US metropolitan area. JAMA: The Journal of the American Medical Association, 289, 49–55. CrossRef

Titel: Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial
Auteurs: Gahan J. Pandina
Cynthia A. Bossie
Eriene Youssef
Young Zhu
Fiona Dunbar
Publicatiedatum: 01-02-2007
Uitgeverij: Kluwer Academic Publishers-Plenum Publishers
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 2/2007
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-006-0234-7

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2007

Brief Report: Identical Male Twins Concordant for Asperger’s Disorder

Assessing the Early Characteristics of Autistic Disorder using Video Analysis

Initial Characteristics of Psychological Development and Evolution of the Young Autistic Child

MMR-Vaccine and Regression in Autism Spectrum Disorders: Negative Results Presented from Japan

Short Breaks Services for Children with Autistic Spectrum Disorders: Factors Associated with Service Use and Non-use

Autobiographical Memory and Social Problem-solving in Asperger Syndrome